NCT06084104View on ClinicalTrials.gov

DZD9008 PK Study in Hepatic Impairment Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 17, 2023

Primary Completion Date

June 12, 2024

Study Completion Date

October 23, 2024

Conditions
Hepatic Impairment
Interventions
DRUG

DZD9008

A single oral dose of 200mg DZD9008

DRUG

DZD9008

A single oral dose of 200mg DZD9008

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

78215

American Research Corporation, San Antonio

Sponsors

Collaborators (1)

PPD Development, L.P.
All Listed Sponsors
collaborator

PPD Development, L.P.

UNKNOWN

lead

Dizal Pharmaceuticals

INDUSTRY